RS
Therapeutic Areas
Cardiff Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Onvansertib + FOLFIRI/Bevacizumab | RAS-mutated Metastatic Colorectal Cancer (2L+) | Phase 2 |
| Onvansertib + Abiraterone/Prednisone | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 |
| Onvansertib + Nanoliposomal Irinotecan/5-FU/LV | Metastatic Pancreatic Ductal Adenocarcinoma (2L) | Phase 2 |
| Onvansertib + Paclitaxel | Metastatic Triple-Negative Breast Cancer | Phase 1b/2 |
| Onvansertib + Carboplatin/Etoposide | Small Cell Lung Cancer (1L Extensive-Stage) | Phase 1b/2 |
| Onvansertib (Single Agent) | Chronic Myelomonocytic Leukemia (CMML) | Phase 2 |
| Onvansertib + Radiation | Medulloblastoma | Preclinical |
| Onvansertib + PARP Inhibitors | Ovarian Cancer | Preclinical |